Ignyta, Inc. (RXDX)
(Real Time Quote from BATS)
$26.95 USD
+0.03 (0.09%)
Updated Feb 8, 2018 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
RXDX 26.95 +0.03(0.09%)
Will RXDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RXDX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RXDX
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?
RXDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech ETFs Pop on M&A Resurgence
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Misses Revenue Estimates